Anteris Technologies (AVR) investor relations material

Executive summary

• Focused on developing and commercializing the DurAVRⓇ Transcatheter Heart Valve (THV) System for aortic stenosis and structural heart disease, with ongoing pivotal PARADIGM Trial and recent U.S. Medicare reimbursement eligibility for trial procedures.

• Report covers the quarter ended 31 March 2026, prepared under U.S. GAAP and denominated in USD.

• Completed major capital raises in January 2026, including a $230M public offering and $90M private placement with Medtronic, supporting operational scale-up.

• Revenue remains limited as the company is pre-commercialization, with continued investment in R&D and manufacturing expansion.

Financial highlights

• Net sales for Q1 2026 were $0.5M, down from $0.6M year-over-year, reflecting the end of a distribution agreement with LeMaitre and increased sales to 4C Medical Technologies.

• Net loss attributable to stockholders was $23.0M for Q1 2026, compared to $21.9M in Q1 2025.

• R&D expenses rose 6% year-over-year to $17.5M, driven by manufacturing scale-up and clinical trial activities.

• Selling, general and administrative expenses increased 22% to $6.9M, mainly due to higher personnel and consulting costs.

• Cash and equivalents at March 31, 2026 were $283.2M, up from $12.6M at year-end 2025, reflecting capital raises.

Outlook and guidance

• Expects continued operating losses and negative cash flows until regulatory approval and commercialization of DurAVRⓇ THV.

• Current cash position is projected to fund operations for at least the next 12 months.

• Ongoing expansion of clinical trial sites and manufacturing capacity to support pivotal trial and future commercialization.